SEASTAR MEDICAL HOLDING CORP (ICU)
NASDAQHealth CareBiotechnologySnapshot 2026-09-09
$3.10+5.08%
Close 2026-09-09 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-09
Intact: The reason to own it still holds.
SeaStar aims for $2 million in product sales in 2026. Revenue grew from $420,000 to $495,000 in early 2026. Operating losses are shrinking, improving from negative $4.8 million to negative $3.6 million. The company is in a growing market with strong research and partnerships.
SeaStar is still losing money and revenue is low. Growth may slow or stop. Executive changes and lawsuits add risks.
The price is about 11% below our fair value near $6. Analysts expect 62% revenue growth. Our view is cautious due to losses and execution risks.
Breaks if: unexpected termination of key executives occurs
Breaks if: net product revenue falls below $1.5 million in FY26
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a turnaround scenario with a focus on long-term growth. The current thesis state indicates a watchful approach due to recent volatility in management and mixed financial performance.
The market appears to have priced in a low level of fragility, suggesting that expectations are somewhat justified. ICU is currently viewed as cheaper compared to its peers, but there is a notable expectations gap indicating that the market may be cautious about future performance.
Management is focused on expanding its pediatric customer base and advancing clinical trials, but recent changes in management and company momentum raise concerns. The likelihood of missing earnings remains relatively high, which could impact investor sentiment.
The future performance of ICU hinges on the outcomes of key clinical trials and the ability to secure FDA approvals. Additionally, broader sector trends and economic indicators, such as job reports, will play a crucial role in shaping investor expectations.
The most important moves since the prior daily snapshot.
Mixed, the news cuts both ways. The company is expanding its QUELIMMUNE customer base. This growth supports revenue for pediatric AKI. However, it missed earnings forecasts for Q2 2026. This miss challenges its goal of achieving $2 million in revenue for 2026.
as of 2026-09-09
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Focus on reaching approximately $2 million in net product revenue during fiscal year 2026.
Breaks if: operating loss worsens beyond negative $4 million in FY26
Over the next 1 to 3 years, ICU's performance will depend on its execution of strategic priorities and external market conditions. Not investment advice.